CTRN
Citi Trends, Inc.
CTRN has the edge over GME overall, supported by stronger modeled upside and lower modeled downside.
GME
GameStop Corp.
GME offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
CTRN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Strong |
CTRN's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
GME Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Unavailable |
GME's profitability and cash flow are currently strong, and its revenue is stable. There isn't enough data to rate its balance sheet.
CTRN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 3.8x | $3.31 | -92% |
| Fair | 10x | $8.73 | -80% |
| Forward | 19x | $43.05 | — |
| Expensive | 46x | $39.40 | -8.5% |
| Current | 50x | $43.05 | — |
Historical ranges are pointers, not guarantees.
CTRN's PE is in its expensive range at 50x. If earnings grow as analysts expect, today's price would be 19x next year's earnings, in its fair range.
GME PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 17x | $25.62 | — |
| Cheap | 18x | $27.96 | +9.1% |
| Forward | 38x | $25.62 | — |
| Fair | 43x | $66.84 | +161% |
| Expensive | 252x | $388 | +1414% |
Historical ranges are pointers, not guarantees.
GME has the edge over CTRN in the historical PE scenario, which offers more potential upside but is not a forecast.
CTRN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
CTRN has the edge over GME on the outlook, with more favorable valuation and earnings expectations.
GME Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong decline | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect GME's earnings and revenue to decline, with profitability weakening.
CTRN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.33 | +170% |
| Q3 2026 | $0.86 | +$2.85 |
| Q2 2026 | $1.43 | +$6.09 |
| Q1 2026 | $0.63 | +$5.82 |
| Q4 2025 | -$1.99 | +$1.07 |
| Q3 2025 | -$1.99 | +$0.68 |
| Q2 2025 | -$4.66 | -$3.59 |
| Q1 2025 | -$5.19 | -$3.73 |
| Q4 2024 | -$3.06 | -$2.04 |
CTRN has returned to profit: it earned $0.86 per share over the past year, after losing money the year before.
GME Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.67 | -56% |
| Q3 2026 | $1.54 | +93% |
| Q2 2026 | $1.34 | +153% |
| Q1 2026 | $0.77 | +133% |
| Q4 2025 | $0.89 | +394% |
| Q3 2025 | $0.80 | +515% |
| Q2 2025 | $0.53 | +563% |
| Q1 2025 | $0.33 | +1550% |
| Q4 2024 | $0.18 | +$0.21 |
GME has the edge over CTRN on earnings, with more consistent year-over-year improvement.
CTRN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $211.6M | +11% |
| Q2 2026 | $230.9M | +14% |
| Q1 2026 | $230.4M | +9.1% |
| Q4 2025 | $197.1M | +10% |
| Q3 2025 | $190.8M | +8% |
| Q2 2025 | $201.7M | +8.3% |
| Q1 2025 | $211.2M | -1.9% |
| Q4 2024 | $179.1M | -0.3% |
CTRN has the edge over GME on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -0.8% | -2.7 points |
| Q2 2026 | 3.2% | +3 points |
| Q1 2026 | 3.1% | +2.6 points |
| Q4 2025 | -3.7% | +1.2 points |
| Q3 2025 | 1.8% | +16 points |
| Q2 2025 | 0.2% | +4 points |
| Q1 2025 | 0.6% | -1.3 points |
| Q4 2024 | -4.9% | -1.6 points |
CTRN's operating margin was −0.8% last quarter, down 2.7 points from the same quarter a year ago.
GME Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $790.2M | -19% |
| Q2 2026 | $835.3M | +14% |
| Q1 2026 | $1.1B | -14% |
| Q4 2025 | $821M | -4.6% |
| Q3 2025 | $972.2M | +22% |
| Q2 2025 | $732.4M | -17% |
| Q1 2025 | $1.3B | -28% |
| Q4 2024 | $860.3M | -20% |
GME's revenue has slid since its 2022 peak: $790M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +13 points |
| Q2 2026 | 17% | +19 points |
| Q1 2026 | 12% | +6 points |
| Q4 2025 | 5% | +8.9 points |
| Q3 2025 | 6.8% | +9.6 points |
| Q2 2025 | -1.5% | +4.3 points |
| Q1 2025 | 6.2% | +3.1 points |
| Q4 2024 | -3.9% | -2.5 points |
GME has the edge over CTRN on profitability, with a higher operating margin.
CTRN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$24M | -$22.2M |
| Q2 2026 | $15M | +$28.1M |
| Q1 2026 | $14.7M | -44% |
| Q4 2025 | $767K | +$21.2M |
| Q3 2025 | -$1.7M | -205% |
| Q2 2025 | -$13.1M | +$8.1M |
| Q1 2025 | $26M | +30% |
| Q4 2024 | -$20.4M | -$12.8M |
CTRN's free cash flow has turned positive after four years mostly in the red: $6M over the past year.
GME Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $60.7M | -46% |
| Q2 2026 | $332.9M | +76% |
| Q1 2026 | $187.4M | +18% |
| Q4 2025 | $107M | +435% |
| Q3 2025 | $113.3M | +73% |
| Q2 2025 | $189.6M | +$304.3M |
| Q1 2025 | $158.8M | +$177.5M |
| Q4 2024 | $20M | +80% |
GME has the edge over CTRN on cash flow, with more consistent year-over-year improvement.
CTRN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.5% | -301K shares |
| 1 year | -1.6% | -130K shares |
| 3 years | -0.5% | -41.4K shares |
| 5 years | -11% | -995K shares |
| Available history | -30% | -3.5M shares |
CTRN has the edge over GME on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $6.3M |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | $4.7M |
| Q2 2022 | $5.3M |
GME Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +300K shares |
| 1 year | +8.4% | +46.1M shares |
| 3 years | +94% | +288M shares |
| 5 years | +104% | +302M shares |
| Available history | +80% | +264M shares |
GME has 593M diluted shares, up 8.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q1 2020 | $21.8M |
| Q4 2019 | $114M |
CTRN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.2x | Net Cash |
| Q2 2026 | -2.7x | Net Cash |
| Q1 2026 | -3.0x | Net Cash |
| Q4 2025 | -3.2x | Net Cash |
| Q3 2025 | -3.5x | Net Cash |
| Q2 2024 | -27.2x | Net Cash |
| Q4 2023 | -20.2x | Net Cash |
| Q3 2023 | -1.6x | Net Cash |
CTRN has more cash than debt.
GME Net Leverage
CTRN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.5 | Neutral |
| Stochastic | 6.0 | Oversold |
CTRN's weekly RSI is 39 (neutral) and its Stochastic is 6 (oversold).
GME Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.9 | Neutral |
| Stochastic | 68.5 | Neutral |
GME's weekly RSI is 60 (neutral) and its Stochastic is 69 (neutral).
CTRN PE vs Consumer Cyclical Sector
| Metric | CTRN | Sector median | Relative |
|---|---|---|---|
| PE | 50x | 18x | 178% above |
| PE % | 86 | 47 | 39 pts above |
CTRN is trading at 50x earnings, a 178% premium to the Consumer Cyclical sector's median of 18x.
GME PE vs Consumer Cyclical Sector
| Metric | GME | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 18x | 7.7% below |
| PE % | 15 | 47 | 32 pts below |
GME has the edge over CTRN on valuation relative to its sector.
CTRN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $47.4 | 9.1% below |
| 20 week MA | $57.9 | 26% below |
| 50 week MA | $50.8 | 15% below |
| 100 week MA | $40.1 | 7.4% above |
| 200 week MA | $31.2 | 38% above |
CTRN has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 38% above its 200-week average.
GME Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $25.2 | 1.8% above |
| 20 week MA | $22.4 | 15% above |
| 50 week MA | $22.6 | 13% above |
| 100 week MA | $24.0 | 7% above |
| 200 week MA | $21.8 | 17% above |
GME has the edge over CTRN on trend strength, trading above more of its moving averages.
CTRN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $22.8 | $47.4 | +108% |
| 2021 | $47.4 | $76.4 | +61% |
| 2022 | $76.4 | $27.6 | -64% |
| 2023 | $27.6 | $28.3 | +2.4% |
| 2024 | $28.3 | $26.9 | -5.1% |
| 2025 | $26.9 | $40.2 | +50% |
| 2026 YTD | $40.2 | $43.1 | +7.2% |
CTRN's yearly returns have swung widely, from +108% in 2020 to −64% in 2022. It's up 7.2% so far in 2026.
GME Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.48 | $5.04 | +241% |
| 2021 | $5.04 | $38.0 | +655% |
| 2022 | $38.0 | $20.1 | -47% |
| 2023 | $20.1 | $17.5 | -13% |
| 2024 | $17.5 | $32.2 | +84% |
| 2025 | $32.2 | $21.1 | -35% |
| 2026 YTD | $21.1 | $25.6 | +21% |
GME has the edge over CTRN on returns for 2026, with the stronger performance.